CRSP presents Phase 1a CTX310 data at ESC Congress 2026
CRISPR Therapeutics presented Phase 1a data for CTX310 at ESC Congress 2026, including ANGPTL3 editing and triglyceride and LDL lowering.
Story updates
02:37:42 PM UTC
SquawkNews
CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.